Trial reportMicrobial drug resistance (Larchmont, N.Y.)2020
High Prevalence of Fecal Carriage of Extended Spectrum β-Lactamase-Producing Enterobacteriaceae Among Newly HIV-Diagnosed Adults in a Community Setting in Tanzania.
Trial report in Microbial drug resistance (Larchmont, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Pooled it
- Navigating the trials of a trial: lessons from ProRIDE on recruitment, retention, and follow-up in rural Africa.Trials · 2026Trial
- Risk Factors for Community Colonization With Extended-Spectrum Cephalosporin-Resistant Enterobacterales Among People Living With HIV in Botswana.Open forum infectious diseases · 2026Article
- Associations of HIV status and the abundance of blaCTX-M and vanB resistance genes in stool samples of Ghanaian individuals.European journal of microbiology & immunology · 2025Article
- Article
- Faecal carriage of extended-spectrum beta-lactamase and carbapenemase-producing enterobacterales among HIV patients at Jimma Medical Center, Southwest Ethiopia.BMC microbiology · 2024Article
- Multidrug-Resistant Bacteria in Immunocompromised Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Importance of Carbapenemase-Producing Enterobacterales in African Countries: Evolution and Current Burden.Antibiotics (Basel, Switzerland) · 2024Review
- High prevalence of fecal carriage of extended-spectrum beta-lactamase producingFrontiers in microbiology · 2024Article
- Clinical Characteristics, Prognosis and Treatment of Bloodstream Infections withInfection and drug resistance · 2024Article
- Extended Spectrum β-Lactamase Producing Lactose Fermenting Bacteria Colonizing Children with Human Immunodeficiency Virus, Sickle Cell Disease and Diabetes Mellitus in Mwanza City, Tanzania: A Cross-Sectional Study.Tropical medicine and infectious disease · 2022Article
- Colonization of Extended-spectrum β-lactamase producing Enterobacterales and meticillin-resistantInfection prevention in practice · 2022Article
- Multidrug-Resistant and Extended-Spectrum β-Lactamase (ESBL) - ProducingPathogens (Basel, Switzerland) · 2022Article
- Paediatric Enterobacteriaceae infections in hospitalised children in Durban, KwaZulu-Natal.Southern African journal of infectious diseases · 2021Article
Corrections and comments
- Erratum issuedCorrection to:2021
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colonization in HIV-infected populations with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) is particularly worrisome in low-income settings. This study describes the prevalence of ESBL-PE carriage and associated risk factors among newly HIV-diagnosed adults in a community setting in Tanzania. A total of 595 newly diagnosed HIV adults with a median age of 35 years with interquartile range (IQR) 29-42 years and a median CD4 count of 492 cells/μL (IQR 390-666 cells/μL) were recruited. Among these, 194/595 (32.6%, 95% confidence interval [CI] 28.9-36.6) were ESBL-PE carriers. Participants with low CD4 count (<350 cells/μL) had significantly higher prevalence of ESBL-PE carriage compared with those with CD4 count ≥350 cells/μL (26/58, 44.8%, vs. 168/537, 31.3%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.